{{medical}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 461119364
| IUPAC_name = 7-[(4''Z'')-3-(Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo- 1,8-naphthyridine-3-carboxylic acid
| image = Gemifloxacin.svg
<!--Clinical data-->
| tradename =  Factive（吉速星）
| Drugs.com = {{drugs.com|monograph|factive}}
| MedlinePlus = a604014
| pregnancy_category = C
| legal_status = Rx-only
| routes_of_administration = 口服給藥、靜脈給藥（研發中）
<!--Pharmacokinetic data-->
| bioavailability = 71%
| protein_bound = 60–70%
| metabolism = 肝臟，不完整代謝
| excretion = 糞便排除（61%）、尿液排除（36%）
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 175463-14-6
| ATC_prefix = J01
| ATC_suffix = MA15
| PubChem = 9571107
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01155
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 7845573
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = OKR68Y0E4T
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D08012
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 101853
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 430
<!--Chemical data-->
| C=18 | H=20 | F=1 | N=5 | O=4
| smiles = Fc2c(nc1N(/C=C(/C(=O)O)C(=O)c1c2)C3CC3)N4C/C(=N\OC)C(C4)CN
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZRCVYEYHRGVLOC-HYARGMPZSA-N
}}
'''吉米沙星'''（'''Gemifloxacin，'''原研药商品名'''Factive''' ，中文原研药商品名'''吉速星'''）是一种广谱喹诺酮类[[抗细菌药|抗菌]]剂，由韩国[[LG化学|LG生命科学]]研发，用于治疗慢性[[支气管炎|支气管炎]]和轻度至中度[[肺炎|肺炎]]的急性细菌急性发作，属于呼吸道喹诺酮的一种。该药以口服甲磺酸盐（即'''甲磺酸吉米沙星'''）的形式应用于临床。

== 临床应用 ==
吉米沙星适用于在下列情况下治疗由指定微生物的敏感菌株引起的感染。

* 由[[肺炎鏈球菌|肺炎链球菌]]、[[流感嗜血桿菌|流感嗜血杆菌]]、副流感嗜血杆菌或卡他莫拉菌引起的慢性支气管炎
* 由肺炎链球菌（包括多重耐药菌株）、流感嗜血杆菌、卡他莫拉菌、[[肺炎支原體|肺炎支原体]]、肺炎[[衣原體門|衣原体]]或[[克雷伯氏肺炎菌|肺炎克雷伯菌]]）引起的社区获得性肺炎

== 抗菌谱 ==
已经证明吉米沙星对下列微生物的大多数菌株具有活性：
*[[革蘭氏陽性菌|革兰氏阳性菌]]<ref name="Calvo2002">{{Cite journal|title=Ex Vivo Serum Activity (Killing Rates) After Gemifloxacin 320 mg Versus Trovafloxacin 200 mg Single Doses Against Ciprofloxacin-Susceptible and -Resistant Streptococcus pneumoniae|date=2002|journal=Int. J. Antimicrob. Agents|issue=2|doi=10.1016/S0924-8579(02)00119-X|volume=20|pages=144–6|pmid=12297365}}</ref>：包括肺炎链球菌（含多药耐药性肺炎链球菌（MDRSP）、耐青霉素的肺炎链球菌（PRSP））、[[金黃色葡萄球菌|金黄色葡萄球菌]]和化脓性链球菌
*[[革兰氏阴性菌|革兰氏阴性菌]]：包括流感嗜血杆菌、副流感嗜血杆菌、[[克雷伯氏肺炎菌|肺炎克雷伯菌]]、卡他莫拉菌、[[鮑氏不動桿菌|鲍曼不动杆菌]]、产酸克雷伯菌、[[嗜肺军团菌|嗜肺军团菌]]、寻常变形杆菌。
*其他微生物：肺炎衣原体，肺炎支原体

== 不良反应 ==
氟喹诺酮类药物一般耐受良好，大多数副作用是轻度的，很少出现严重的不良反应。 <ref name="Robert2005">{{Cite journal|title=Antimicrobial safety: focus on fluoroquinolones|date=July 2005|journal=Clin. Infect. Dis.|doi=10.1086/428055|volume=41 Suppl 2|pages=S144–57|pmid=15942881}}</ref><ref name="Bel1999">{{Cite journal|title=Comparative tolerability of the newer fluoroquinolone antibacterials|date=November 1999|journal=Drug Saf|issue=5|doi=10.2165/00002018-199921050-00005|volume=21|pages=407–21|pmid=10554054}}</ref>与其他抗生素类药物相比，氟喹诺酮类特有的一些严重不良反应包括中枢神经系统毒性和跟腱炎。<ref name="Owens RC, Ambrose PG 2005 S144–57">{{Cite journal|title=Antimicrobial safety: focus on fluoroquinolones|url=http://www.journals.uchicago.edu/cgi-bin/resolve?CID34940|date=July 2005|journal=Clin. Infect. Dis.|doi=10.1086/428055|volume=41 Suppl 2|pages=S144–57|pmid=15942881|access-date=2020-12-15|archive-date=2019-08-03|archive-url=https://web.archive.org/web/20190803105807/https://www.journals.uchicago.edu/cgi-bin/resolve%3FCID34940|dead-url=no}}</ref><ref name="pmid17559736">{{Cite journal|title=The safety profile of moxifloxacin and other fluoroquinolones in special patient populations|last=Iannini PB|date=June 2007|journal=Curr Med Res Opin|issue=6|doi=10.1185/030079907X188099|volume=23|pages=1403–13|pmid=17559736}}</ref>

吉米沙星在治疗剂量下可能会发生严重不良反应，它们包括：中枢神经系统毒性、心血管毒性、肌腱/关节毒性。 在药物过量的情况下可能会导致肾衰竭和癫痫发作。儿童和老人发生副作用的风险更大。<ref name="Robert2005">{{Cite journal|title=Antimicrobial safety: focus on fluoroquinolones|date=July 2005|journal=Clin. Infect. Dis.|doi=10.1086/428055|volume=41 Suppl 2|pages=S144–57|pmid=15942881}}</ref><ref name="pmid17559736">{{Cite journal|title=The safety profile of moxifloxacin and other fluoroquinolones in special patient populations|last=Iannini PB|date=June 2007|journal=Curr Med Res Opin|issue=6|doi=10.1185/030079907X188099|volume=23|pages=1403–13|pmid=17559736}}</ref><ref name="pmid10970974">{{Cite journal|title=[Rupture of the patellar ligament one month after treatment with fluoroquinolone]|url=http://www.masson.fr/masson/MDOI-RCO-09-2000-86-5-0035-1040-101019-ART7|date=September 2000|journal=Rev Chir Orthop Reparatrice Appar mot|issue=5|volume=86|pages=495–7|language=fr|pmid=10970974}}</ref>

与其他氟喹诺酮类药物相比，吉米沙星对心血管系统的毒性较为突出。<ref>{{Cite news|url=http://www.cnn.com/2008/HEALTH/07/08/antibiotics.risk/index.html|title=FDA orders 'black box' label on some antibiotics|accessdate=2008-07-08|work=CNN|date=2008-07-08|archive-date=2017-11-07|archive-url=https://web.archive.org/web/20171107221712/http://www.cnn.com/2008/HEALTH/07/08/antibiotics.risk/index.html|dead-url=no}}</ref>

== 相关研究 ==
一项最新研究表明，吉米沙星在体外细胞和小鼠体内均具有抗[[乳癌|乳腺癌]]转移活性。<ref name="pmid = 24005829">{{Cite journal|title=Gemifloxacin inhibits migration and invasion and induces mesenchymal-epithelial transition in human breast adenocarcinoma cells|last=Chen TC|date=Jan 2014|journal=J Mol Med (Berl)|issue=1|doi=10.1007/s00109-013-1083-4|volume=92|pages=53–64|pmid=24005829}}</ref>

== 参见 ==
* [[喹诺酮|氟喹诺酮]]

== 参考文献 ==
{{Reflist|2}}
{{核酸合成抑制剂类抗生素}}

[[Category:环丙基化合物|Category:环丙基化合物]]
[[Category:LG集团|Category:LG集团]]
[[Category:喹诺酮抗生素|Category:喹诺酮抗生素]]